Uzm. Dr. Gözde Ağdaş

Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

BMC Cancer, 2026

DOI 10.1186/s12885-026-16868-5 Frei zugänglicher VolltextQuelle: OpenAlex

Meme Kanseri

Akademisyen Kitabevi eBooks, 2026

DOI 10.37609/akya.3852 Frei zugänglicher VolltextQuelle: OpenAlex

Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15020642 PMID 41598581 Frei zugänglicher VolltextQuelle: ORCID

Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients

Scientific reports, 2026

DOI 10.1038/s41598-026-50526-x PMID 42103792 Frei zugänglicher VolltextQuelle: Europe PMC

The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer

Discover oncology, 2026

DOI 10.1007/s12672-026-04705-x PMID 41721952 Frei zugänglicher VolltextQuelle: Europe PMC

Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab

Scientific reports, 2026

DOI 10.1038/s41598-026-48955-9 PMID 41981174 Frei zugänglicher VolltextQuelle: Europe PMC

Impact of renin-angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non-small cell lung cancer

Expert review of anticancer therapy, 2026

DOI 10.1080/14737140.2026.2615853 PMID 41511755 2 Zitationen (Europe PMC) Quelle: ORCID

Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumab

Discover Oncology, 2026

DOI 10.1007/s12672-026-04859-8 PMID 42014558 Frei zugänglicher VolltextQuelle: OpenAlex

Integrating molecular and clinical determinants of survival in a real-world glioblastoma cohort

Journal of Medicine and Palliative Care, 2026

DOI 10.47582/jompac.1850445 Frei zugänglicher VolltextQuelle: ORCID

IMMUNE-RELATED ADVERSE EVENTS AND THEIR MANAGEMENT IN CANCER PATIENTS AGED 75 YEARS AND OLDER RECEIVING IMMUNOTHERAPY

Acta Medica Nicomedia, 2026

DOI 10.53446/actamednicomedia.1906747 Frei zugänglicher VolltextQuelle: ORCID

Real-world outcomes of first-line THP in de-novo HER2-positive metastatic breast cancer: a retrospective analysis of prognostic factors Including hormone receptor status, performance status, and metastatic pattern

Journal of Health Sciences and Medicine, 2026

DOI 10.32322/jhsm.1943147 Frei zugänglicher VolltextQuelle: ORCID

Comparison of perioperative chemotherapy and neoadjuvant chemoradiotherapy (CRT) in locally advanced resectable distal esophageal/esophagogastric junction (EGJ) adenocarcinomas

BMC Cancer, 2026

DOI 10.1186/s12885-026-16110-2 PMID 42151898 Frei zugänglicher VolltextQuelle: ORCID

Evaluation of the frequency of Helicobacter pylori infection and atrophic gastritis in patients diagnosed with celiac disease

Turkish Journal of Clinics and Laboratory, 2026

DOI 10.18663/tjcl.1804461 Frei zugänglicher VolltextQuelle: ORCID

The prognostic impact of anemia in recurrent esophageal squamous cell carcinoma

Anatolian Current Medical Journal, 2026

DOI 10.38053/acmj.1827779 Frei zugänglicher VolltextQuelle: ORCID

Prognostic Impact of RAS Mutation and Biologic Therapy in Second-Line Treatment of De-Novo Metastatic Colorectal Cancer: A Real-World Retrospective Analysis

Eurasian Journal of Medical Investigation, 2026

DOI 10.14744/ejmi.269385 Quelle: ORCID

Predicting the Effectiveness of 2 Chemotherapy Regimens Applied to Breast Cancer Patients by Nutritional and Inflammatory Status

Medical science monitor : international medical journal of experimental and clinical research, 2026

DOI 10.12659/msm.951548 PMID 41572592 Frei zugänglicher VolltextQuelle: Europe PMC

Baseline Tumor Biology Predicts Survival After Recurrence in Gastric Cancer: Impact of LVI, PNI, and HER2 Status

Medical science monitor : international medical journal of experimental and clinical research, 2026

DOI 10.12659/msm.951829 PMID 41508562 Frei zugänglicher VolltextQuelle: Europe PMC

Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective study

Frontiers in Immunology, 2026

DOI 10.3389/fimmu.2026.1714533 PMID 41766853 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Hormon Reseptörü Pozitif ve HER2 Negatif Meme Kanserinde Neoadjuvan Tedavi

Akademisyen Kitabevi eBooks, 2026

DOI 10.37609/akya.3852.c2768 Quelle: OpenAlex

Prognostic evaluation of dirty necrosis and tumor necrosis in gastric cancers

Scientific Reports, 2026

DOI 10.1038/s41598-026-39605-1 PMID 41673085 Frei zugänglicher VolltextQuelle: OpenAlex

Efficacy of Subsequent Therapy in Patients with Hormone-Positive Advanced Breast Cancer with Disease Progression After CDK4/6 Inhibitor Therapy: Multicenter Real-Life Data

Journal of Clinical Medicine, 2025

DOI 10.3390/jcm14207376 PMID 41156245 Frei zugänglicher VolltextQuelle: ORCID

The prognostic utility of the ESGO risk classification in endometrial carcinoma: a single-center retrospective cohort study

Journal of Medicine and Palliative Care, 2025

DOI 10.47582/jompac.1822658 Frei zugänglicher VolltextQuelle: ORCID

Can Symptom Clusters Predict Stage, Resectability, and Survival in Pancreatic Cancer?

Cancer Management and Research, 2025

DOI 10.2147/cmar.s561301 PMID 41356429 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Prognostic Significance of High-Risk versus Very High-Risk Classification in Non-Surgically Managed Prostate Cancer: A Retrospective Cohort Study

Cancer Management and Research, 2025

DOI 10.2147/cmar.s570916 PMID 41480518 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

A Novel Non-Invasive Biomarker for Gastric Cancer: Monocyte-to-HDL Ratio and Clinicopathological Parameters in Predicting Survival Outcomes

Cancers, 2025

DOI 10.3390/cancers17172816 PMID 40940914 3 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Çölyak hastalığı tanılı hastalarda Helicobacter pylori enfeksiyonu ve atrofik gastrit sıklığının değerlendirilmesi

DergiPark (Istanbul University), 2025

Quelle: OpenAlex

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

The Oncologist, 2023

DOI 10.1093/oncolo/oyad257 PMID 37676712 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex